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Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1 
Reactive Oxygen Species in the  
Biology of Melanoma 
Irene L. Ibañez1,2, Cintia Notcovich1,  
Lucía L. Policastro1,2 and Hebe Durán1,2,3 
1Comisión Nacional de Energía Atómica; 
 2Consejo Nacional de Investigaciones Científicas y Técnicas; 
 3Escuela de Ciencia y Tecnología,  Universidad Nacional de San Martín; 
Argentina 
 
1. Introduction  
The incidence of melanoma has been increasing at an alarming rate worldwide. Although 
melanoma accounts for only 10% of skin cancer, it is responsible for at least 80% of skin 
cancer deaths. Malignant melanoma remains one of the cancers most resistant to treatment. 
Moreover, no effective therapy exists to inhibit the metastatic spread of this type of cancer. 
Research to further understanding of how melanoma cells differ from normal tissues is 
essential to make the discovery of potential new ways of attack. Increased reactive oxygen 
species (ROS) levels have been associated with numerous pathological conditions, including 
cancer. Particularly, melanoma cells constituvely produce high amounts of ROS as 
compared with their non-tumoural counterpart, melanocytes (Policastro et al, 2009). In 
relation to this, one promising strategy relates to the development of new therapies taking 
advantage of the excess of ROS produced by melanomas. In this chapter, we review: our 
current understanding of the involvement of ROS in cancer and particularly in the biology 
of melanocytes and melanoma, therapeutic approaches related to intracellular ROS 
modulation and emerging gene therapy strategies based on intracellular ROS levels of 
melanoma. 
1.1 Role of reactive oxygen species in cancer 
In order to further understand the involvement of ROS in the biology of melanoma, we will 
briefly introduce state-of–the-art advances regarding ROS and cancer. ROS are largely 
generated as oxidative by-products of normal cellular metabolism which include highly 
reactive radicals (e.g. superoxide anion, O2●– and hydroxil radical ●OH) and milder oxidants 
such as hydrogen peroxide (H2O2). ROS were traditionally considered as toxic products 
leading to cellular damage. However, at physiological concentrations, some of these species 
are involved in the regulation of cellular processes and their levels are tightly controlled by 
specific antioxidant scavenging systems (Halliwell & Gutteridge, 2007). Antioxidants can be 
synthesized in vivo or taken from the diet. These antioxidant defences contribute to preserve 
the redox state of cell in homeostatic balance and they comprise enzymes, like superoxide 
dismutase (SOD), catalase, glutathione peroxidase (GPx), peroxiredoxins and non-enzymatic 
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agents such as low molecular weight antioxidants (Fig. 1). Differences in level and 
composition of antioxidant defences can be found from tissue to tissue and cell type to cell 
type within a given tissue depending on which ROS are generated, the manner, the time and 
which of the targets is affected (Halliwell & Gutteridge, 2007).  
An imbalance between ROS generation and their removal may induce an oxidative stress or 
a prooxidant state, which in turn may result in increased proliferation, adaptation, cell 
injury, apoptosis, senescence, cytotoxicity and cell death. On the other hand, physiological 
levels of ROS are necessary for proper functioning of cellular processes such as proliferation, 
whereas scavenging of H2O2 inhibits cell proliferation (Stone & Yang, 2006). 
ROS have been reported to be involved in over 150 human disorders, e.g. atherosclerosis 
and cardiovascular diseases, autoimmune and neurodegenerative disorders and cancer 
(Halliwell & Gutteridge, 2007). ROS may play a role in tumour development, not only as 
DNA-damaging agents that increase the mutation rate and promote oncogenic 
transformation (Halliwell, 2007) but also as mediators of signal transduction pathways 
related to cell proliferation, angiogenesis and migration (Nishikawa, 2008).  
 
 
 
 
Fig. 1. Antioxidant defence systems. (A) Enzymatic and (B) Non-enzymatic antioxidant 
defences 
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One of the major endogenous sources of DNA damage is that produced by ROS (Jackson & 
Loeb, 2001). It has been estimated that approximately 20,000 bases in DNA are damaged in 
each human cell per day by ROS (Jackson & Loeb, 2001). Some of the oxidative modified 
bases constitute blocks to replication, while others are able to misrepair at high frequency, 
leading to base substitutions (Jackson & Loeb, 2001). Thus, DNA damage induced by ROS in 
cells exposed to a prooxidant state could result in an overwhelming mutational load that 
could contribute to carcinogenesis. Indeed, many chemical carcinogens act through free 
radical metabolites (Guyton & Kensler, 1993), some tumour promoters stimulate the 
production of free radicals in several cell types and tissues (Cerutti, 1985; Duran & de Rey, 
1991), whereas free radical-scavengers protect against cancer development in animal models 
(Hyoudou et al, 2009) and may be chemoprotective in humans (Cerutti, 1985; Guyton & 
Kensler, 1993). In addition, O2●– and H2O2 can enhance cell survival and stimulate 
proliferation. The production of large amounts of H2O2 was reported in cancer cells and 
tissues (breast, colorectal and renal cell carcinoma and melanoma) as compared with its 
non-tumoural counterpart (Policastro et al, 2004; Policastro et al, 2009; Szatrowski & Nathan, 
1991; Toyokuni et al, 1995). This could be attributed in part to deregulation of antioxidant 
enzymes, which could lead to an increased ROS accumulation. Particularly, an increase in 
superoxide dismutase and a decrease in catalase activities were found in epithelial tumour 
cells and in human melanoma cells. In this sense, a correlation between the endogenous 
levels of H2O2 and the degree of malignancy was demonstrated in epithelial tumour cell 
lines from skin, breast and bladder (Hempel et al, 2009; Policastro el al, 2004). These 
characteristics further perpetuate a state of oxidative stress in cancer cells. In agreement 
with this concept, the scavenging of ROS inhibits cell proliferation in tumour cells, as 
described in cells treated with catalase, glutathione (GSH) or N-acetylcysteine (NAC) 
(Laurent et al, 2005; Onumah et al, 2009; Policastro et al, 2004). 
It is well documented that H2O2 is involved in signal transduction pathways (Fig. 2), e.g. 
increased levels of H2O2 induce mitogenic signals, such as those related to epidermal growth 
factor receptor (EGFR)/Ras/ extracellular signal-regulated kinases 1 and 2 (ERK1/2) 
pathway, and stress-responsive signals, such as those related to Jun N-terminal kinases 
(JNKs) and p38 mitogen-activated protein kinase (MAPK) pathways. Moreover, ROS and 
H2O2 were also implied in the modulation of receptor tyrosine kinases (RTK) and 
phosphatidylinositol 3-kinase (PI3K)/AKT pathways (Stone & Yang, 2006). These redox-
dependent signalling cascades converge on core cell cycle regulators (Burhans & Heintz, 
2009). The regulation of cell cycle is highly coordinated by sequential assembly and 
activation of phase-specific protein kinase complexes (Elledge, 1996; Sherr, 1996), formed by 
cyclins and cyclin-dependent kinases (CDKs), which are also regulated by the INK4 proteins 
and the CDK inhibitors (CDKIs). D-type cyclins are expressed throughout the cycle in 
response to mitogen stimulation (Sherr, 1996). Fluctuations observed in the intracellular 
redox state during cell cycle progression could link oxidative metabolic processes to cell 
cycle regulation (Menon et al, 2003; Sarsour et al, 2009). The regulation of cyclin D1 
expression was connected to H2O2 variations along the cell cycle (Burch & Heintz, 2005). 
Thus, the removal of endogenous H2O2 by overexpression of catalase and glutathione 
peroxidase induces G0/G1 arrest (Ibanez et al, 2011; Onumah et al, 2009) and decreases cell 
DNA synthesis (Felty et al, 2005). We demonstrated that the scavenging of H2O2 by catalase 
in tumour cells induced G1/S arrest by modulating the levels of specific regulatory proteins 
of early to mid G1 (cyclin D1) and G1/S transition (p27KIP1). Moreover, we found a 
modification in the intracellular localization of the inhibitory protein p27KIP1. This protein 
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remained in the nucleus where it inhibits the cyclin E-CDK2 complex after catalase 
treatment, whereas it showed cytoplasmic localization in proliferating cells. In addition, we 
demonstrated an increase of p27KIP1 in response to H2O2 scavenging in vivo related to the 
inhibition of tumour growth after catalase treatment in agreement with in vitro results 
(Ibanez et al, 2011). In view of the aforementioned, the prooxidant state of tumour cells may 
confer them a proliferative advantage and contribute to the acquisition of a malignant 
phenotype. 
Furthermore, a role of oxidative stress in the regulation of metastasis and tumour 
progression has been reported.  It is becoming clear that a number of steps in the metastatic 
cascade, such as invasion, intravasation and extravasation, as well as, the angiogenic 
response are regulated by redox signalling. Particularly, ROS increase the expression and/or 
activate matrix metalloproteinases (MMPs), adhesion molecules, EGFR, vascular endothelial 
growth factor (VEGF) and the hypoxia-inducible factor (HIF) transcription factor 
(Nishikawa, 2008; Toullec et al, 2010). In the process of cancer cells forming metastatic 
colonies, active MMPs are required to destroy the extracellular matrix and basement 
membranes for the migration of tumour cells. These cells and their surrounding cells secrete 
MMPs in latent forms which are activated by ROS (Nishikawa, 2008). The H2O2-dependent 
expression of both MMP-9 and VEGF was demonstrated as removal of H2O2 by 
overexpression of catalase attenuated their expression (Hempel et al, 2009). 
In addition, it has been proposed that cancer cells could induce oxidative stress in the 
tumour microenvironment, resulting in the amplification of oxidative stress in a given tissue 
area. This would then provide a mutagenic/oxidative field resulting in widespread ROS 
production and DNA damage. This bystander oxidative stress could favour an increase in 
the mutation rate of adjacent normal epithelial cells or cancer cells, resulting in more 
aggressive cancer cells (Martinez-Outschoorn et al, 2010).  
2. Reactive oxygen species in melanocytes and melanoma 
2.1 ROS in the physiology of melanocytes. Involvement of reactive oxygen species in 
melanogenesis  
The skin represents one of the largest organs of the human body and is a constant target of 
endogenous and exogenous ROS, counteracted by a powerful defence system, particularly, 
the biopolymer melanin functions as an intrinsic free radical trap. Also, the UV properties of 
melanin have a preventive action to protect epidermal proliferating cells (Schallreuter & 
Wood, 2001) 
The pigmentation process takes place in melanocytes, which produce melanin through the 
process called melanogenesis. The specific organelle involved in this process is the 
melanosome, which has the full capacity for the biosynthesis and distribution of both 
eumelanin and pheomelanin. 
Tyrosinase, the key enzyme in melanogenesis, contains two copper atoms in its active site, 
which are primarily coordinated to histidine residues. In its Cu(II) oxidation state, the 
enzyme is inactive representing met-tyrosinase. Consequently met-tyrosinase has to be 
activated by the reduction of the two Cu(II) centres to Cu(I) by single electron donors, such 
as L-DOPA, ascorbic acid or superoxide anion (Schallreuter et al, 2008). Tyrosinase catalyses 
the hydroxylation of L-tyrosine to L-DOPA and the oxidation of this to dopaquinone. These 
quinones evolve through a series of steps, both enzymatically and non-enzymatically, to 
generate several unstable intermediates, which polymerize to melanins (Munoz-Munoz et 
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Fig. 2. ROS involvement in cell cycle regulation. (A) Redox-dependent signalling cascades 
involved in the regulation of G1/S transition in cancer and, in particular, in melanoma.  
(B) Low to moderate levels of ROS may initiate cell cycle division whereas high levels of 
ROS may induce cell cycle arrest, apoptosis, terminal differentiation or cytotoxicity 
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al, 2009). Moreover, L-DOPA is mainly formed from L-tyrosine by tyrosine hydroxylase 
isoform I (THI). Thus, the availability of L-tyrosine is essential for melanocytes. This 
aminoacid is provided by facilitated diffusion and by the intracellular enzymatic conversion 
of the essential aminoacid L-phenylalanine via phenylalanine hydroxylase (PAH) 
(Schallreuter et al, 2008). The activities of PAH, THI and tyrosinase are controlled by the 
cofactor 6-tetrahydrobiopterin (6BH4). High levels of ROS, such as O2●– and H2O2, can 
directly inhibit tyrosinase activity, by leading to structural changes of the enzyme due to the 
presence of cysteine residues susceptible to be oxidized or by deactivation of the enzyme by 
the oxidation of a methionine residue to methionine sulfoxide at the active site. Moreover, 
the oxidation of the cofactor 6BH4 to 6 biopterin may be generated by both H2O2 and also by 
UV-B exposure (Schallreuter et al, 2008; Schallreuter & Wood, 2001). However, low 
concentrations of H2O2, in the micromolar range, are needed to upregulate or activate 
tyrosinase and other proteins related to melanogenesis. In addition, both tyrosine-related 
proteins, TRP1 and TRP2, which are located close to tyrosinase in the melanosomal 
membrane, protect this enzyme from ROS attack. These proteins also contain cysteine rich 
domains, which are targets of H2O2 mediated oxidation. Thus, the levels of ROS and 
particularly of H2O2 are tightly controlled under physiological conditions, maintaining 
redox homeostasis in the melanosome and regulating the melanogenesis process. 
Particularly, catalase is an important antioxidant enzyme that regulates this process by H2O2 
removal. 
Regarding the alterations of melanogenesis in melanoma, the loss of pigmentation is very 
common in advanced and in metastatic lesions because of the dysfunction of melanocyte-
specific proteins involved in melanogenesis (Watabe et al, 2004). The main regulator of 
melanogenesis at the transcriptional level is microphtalmia-associated transcription factor 
(MiTF). This factor controls the expression of all known melanosomal proteins (Levy & 
Fisher, 2011). However, post-transcriptional processes may also be involved in the 
pigmentation phenotype of melanoma, particularly the activation of tyrosinase as an 
important control point for melanin biosynthesis. In this sense, several events have been 
suggested to be involved in the hypopigmentation of amelanotic melanoma, such as 
disruption of melanosomal maturation and alterations on the glycosylation and stability of 
tyrosinase. Moreover, considering the ability of H2O2 to inhibit tyrosinase and other proteins 
involved in the melanogenesis process (Jimenez-Cervantes et al, 2001), the high levels of 
H2O2 associated to a decrease in catalase activity (Picardo et al, 1996; Policastro et al, 2009; 
Szatrowski & Nathan, 1991) would be relevant in the induction of the amelanotic 
phenotype. In addition, the down-regulation of melanocyte differentiation markers was 
preceded by a decrease in microphthalmia transcription factor gene (MITF) expression in 
H2O2-treated melanoma cells. Therefore, it was suggested that oxidative stress may lead to 
hypopigmentation by mechanisms that include a MiTF-dependent downregulation of the 
melanogenic enzymes (Jimenez-Cervantes et al, 2001).  
2.2 Involvement of ROS in the development of melanoma 
Many of the general risk factors for developing melanoma include sun exposure, previous 
melanoma or non-melanoma skin cancer, family history of melanoma and large numbers of 
moles (Satyamoorthy & Herlyn, 2002; Wang et al, 2010). The human melanocyte is 
continuously exposed to reactive biochemical species, but is finely tuned via the intrinsic 
antioxidant and radical properties of melanin to suppress the build-up of an altered redox 
phenotype. Meyskens et al. propose that this control is lost during the development of 
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melanoma (Meyskens et al, 2001), moreover they hypothesize that the disruption of 
melanosomal melanin might be an early event in the etiology of melanoma, leading to 
increased oxidative stress and mutation (Gidanian et al, 2008). 
Sunlight exposure is the major cause of skin cancers, including melanoma. Epidemiological 
studies implicate ultraviolet radiation (UV) B (290-320 nm) and UVA (320-400 nm) in the 
development of nonmelanoma skin cancer and melanoma respectively. Although the action 
of UVB radiation is mediated by specific photoproducts, such as pyrimidine dimers, it is 
well known that UVA acts mainly through the induction of ROS. The most important source 
of H2O2 is represented by the free radicals generated after UV exposition, though H2O2, as a 
product of melanogenesis itself, also plays an important role since it is able to diffuse 
outside the melanosome to reach other cellular compartments. Moreover, structural 
alterations of melanosomal membrane in pigmented melanomas may lead to significant 
leakage of reactive melanin precursors including free radical species (Borovansky et al, 
1991). 
As described in the introduction tumour cells produce high amounts of ROS. Regarding 
melanoma, we demonstrated an increase in the levels of H2O2 in human melanoma cells as 
compared to melanocytes (Policastro, 2009). Figure 3 shows the differences in ROS levels 
between melanocytes and melanoma. Moreover, an imbalance in the antioxidant system has 
been described in human melanomas, which can lead to endogenous generation of ROS and 
to cellular incapability of coping with exogenous peroxidative attacks. In addition, it has 
been proposed that the functional effect of melanin dysregulation is its evolution to a 
prooxidant behaviour (Gidanian et al, 2008) and melanin is able to induce DNA damage. 
Thus, the oxidative stress characteristic of melanoma cells is associated with increased DNA 
damage and high rates of mutation. In relation to this, we demonstrated high levels of basal 
DNA damage in melanoma cells (Ibanez et al, 2009) in agreement with other authors 
(Warters et al, 2005). 
 
     Light
microscopy
DCF
     NHM
melanocytes
        A375
melanoma cells
25 μm  
Fig. 3. ROS levels on normal human melanocytes (NHM) and A375 melanoma cells. 
Representative images of NHM and A375 cells, showing the intracellular ROS levels 
determined by 2’, 7’-dichlorodihydro-fluorescein diacetate (DCFH-DA) assay, as described 
by Tarpey et al., 2004. DCF: oxidized 2’, 7’-dichloro-fluorescein 
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2.3 Redox regulation in melanocytes and melanoma 
Redox regulation of protein activity is an important mechanism involved in the modulation 
of signalling and transcription, as part of the large array of posttranslational modifications, 
including, acetylation, carboxylation, glycosylation, hydroxylation or methylation. Different 
mechanisms for sensing have been observed in the various redox-regulated proteins. While 
in many of them, reactive cysteine(s) residues function as redox sensors, others use the 
metal iron, coordinated in Fe–S clusters as a sensor and, lastly, other use their thiol-
coordinated zinc sites as redox switches stimuli (Shlomai, 2010). 
2.3.1 Redox regulation of transcription factors  
Several master transcription regulators, which control cell growth, development and 
survival have redox control, many of which are involved in the regulation of signalling 
transduction pathways in melanocytes and melanoma.  
2.3.1.1 Hypoxia inducible factors (HIF)  
HIF play a key role in the maintenance of oxygen homeostasis. They are involved in 
facilitating cell survival and energy supply in reduced oxygen condition. HIF activation 
affects principally the shift of energy production by increasing glycolysis and decreasing 
mitochondrial function under hypoxic condition (Denko, 2008). HIF-1, the most studied HIF 
factor, was initially identified by its response to low oxygen concentration, but it is now 
apparent that HIF-1 is also crucial in cancer development and progression including 
angiogenesis and tumour invasion (Harris, 2002). HIF-1 is a heterodimeric complex 
comprised of an unstable and oxygen regulated subunit (HIF-1α) and a constitutively 
expressed subunit (HIF-1ǃ), also referred to as the arylhydrocarbon receptor nuclear 
translocator (ARNT). HIF-1 is constitutively transcribed and translated, however under 
normoxia it is rapidly degraded by the ubiquitin-proteasome system. Under sustained 
hypoxia, degradation of the HIF-subunit is inhibited allowing the protein to accumulate, 
heterodimerize and translocate to the nucleus. Thus, in hypoxia conditions, the functional 
HIF-1 dimer, binds to a consensus core sequence namely hypoxia response elements (HREs) 
in the promoter or enhancer of its target genes (Harris, 2002). 
A large body of evidence suggests that ROS modulate HIF-1 activity. H2O2 and nitric oxide 
(NO) donors were found to stabilize HIF-1, and genetic and pharmacological interventions 
modulating ROS generation have been shown to affect the accumulation of HIF-1α (Brune & 
Zhou, 2007; Kietzmann & Gorlach, 2005). It is well demonstrated that during hypoxia, ROS 
production is increased at complex III levels in mitochondria, and this condition is necessary 
for HIF-1ǂ stabilization during hypoxia (Chandel et al, 1998). 
A direct role of hypoxia in advanced melanoma is slowly starting to emerge (Bedogni & 
Powell, 2009). HIF-1 has been shown to play a critical role in uveal melanoma progression 
and is regarded as one of the critical biomarkers to predict uveal melanoma metastasis 
(Chang et al, 2008; Victor et al, 2006). The overexpression of HIF-1α and HIF-2α in human 
melanoma of the skin was reported, and HIF-2α, along with VEGF and vascular density, 
was associated with poor overall disease survival (Giatromanolaki et al, 2003). Melanoma 
cells have also shown a marked HIF-1α activity under normoxic conditions. 
Immunohistochemistry of malignant melanoma showed the focal expression of HIF-1ǂ in 
cancer tissue independent of regional hypoxia. In this work, it has been demonstrated that 
constitutive HIF-1α activity under normoxic conditions is associated with the ROS 
microenvironment around melanoma cells. The inhibition or induction of ROS decreased or 
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activated, respectively, HIF-1 activity and HIF-1alpha protein expression. In addition, the 
involvement of nuclear factor kappa B (NF-κB) was demonstrated in the regulation of HIF 
expression by ROS in melanoma cells (Kuphal et al, 2010). 
2.3.1.2 Nuclear factor kappa B (NF-κB)  
NF-κB is a conserved inducible transcription factor that plays a key role in the control of a 
diverse range of genes involved in inmunological response, cell proliferation, apoptosis, 
tissue remodelling, cellular responses to stress and oncogenesis (Ghosh & Hayden, 2008). In 
mammalian cells, the NF-κB family comprises five related proteins: p50, p52, RelA (also 
known as p65), c-Rel, and RelB which can homo- and heterodimerize through the rel 
homology domain (RHD). Only RelA, c-Rel, and RelB contain a transcriptional activation 
domain, while p50 and p52 can only activate transcription through heterodimerization with 
RelA, c-Rel, or RelB. NF-κB dimers are generally found inactive in the cytoplasm bound to 
inhibitory proteins IκB (IκB-α and IκB-β). In response to a wide array of stimuli, IκB proteins 
are phosphorylated and NF-κB dimeric complex is released and its nuclear localization 
signal is unmasked. NF-κB translocates to the nucleus, where it can 'turn on' the expression 
of specific genes that have DNA-binding sites for NF-κB (Perkins, 2007). ROS have long 
been known to activate NF-κB; however, the role of redox in NF-κB regulation is apparently 
different in cytoplasm and in the nucleus (Kabe et al, 2005). Whereas in the cytoplasm ROS 
have been described in multiple reports to enhance signal transduction pathways, leading to 
NF-κB activation and translocation into the nucleus, it was shown to significantly inhibit the 
capacity of NF-κB to bind the DNA in the nucleus, a capacity that is consequently restored 
through the action of reducing enzymes (Kabe et al, 2005).  
In melanoma, NF-κB is constitutively active unlike to normal melanocytes and is increased 
under conditions of oxidative stress (Meyskens et al, 1999). In this study, the basal DNA-
binding activity of NF-κB in metastatic melanoma cells was found to increase 4-fold as 
compared with normal melanocytes. This level of binding was paralleled by a 1.5- to 4-fold 
increase in the expression of p50, p65 (RelA), and IκB-α. In contrast, the expression of c-Rel 
was markedly decreased (60%) in melanoma cells as compared with normal melanocytes. 
Following oxidative stress produced by enzyme-generated H2O2, free H2O2, or incubation 
with buthionine sulfoximine, NF-κB binding activity increased 1.5- to 2.5-fold in melanoma 
cells, but only slightly in normal melanocytes (Meyskens et al, 1999). Shattuck-Brandt and 
Richmond reported an endogenous activation of NF-κB in melanoma due to 
posttranslational modification of the inhibitory element IκB, as a result of oxidative 
processes, that enhances its degradation (Shattuck-Brandt & Richmond, 1997). In addition, 
melanoma cell lines that exhibit high or low activity of the membrane-bound gamma-
glutamyl transpeptidase (GGT), a basal source of H2O2 in the extracellular space, were 
associated either with higher or lower levels of NF-κB respectively  (Maellaro et al, 2000). 
Moreover, stimulation or inhibition of GGT activity in higher GGT activity cells resulted in 
progressive activation or inactivation of NF-κB, respectively. A role of NAD(P)H oxidase 
and NAD(P)H:quinone oxidoreductase in oxidant signalling of melanoma cell growth has 
also been demonstrated by activating the redox-regulated NF-κB transcription factor (Brar et 
al, 2003).  
2.3.1.3 Activating protein 1 (AP-1) 
AP-1 is a dimeric transcription factor comprising proteins from several families whose 
common denominator is the possession of basic leucine zipper (bZIP) domains that are 
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essential for dimerization and DNA binding. The Jun (c-Jun, JunB and JunD) and Fos (c-Fos, 
FosB, Fra1 and Fra2) subfamilies are the major AP-1 proteins. Activating transcription factor 
(ATF) proteins ATF2, LRF1/ATF3, B-ATF, JDP1 and JDP2 are also components of AP-1. The 
last group of AP-1 proteins, and the least studied, is the Maf subfamily, which includes c-
Maf, MafB, MafA, MafG/F/K and Nrl (Eychene et al, 2008). Different combinations of these 
proteins in the AP-1 complex bind to their specific DNA consensus sequences, determining 
which genes are regulated (Chinenov & Kerppola, 2001). AP-1 family is involved in the 
regulation of central cellular processes, including cell proliferation, survival, growth, 
differentiation, apoptosis, migration, and transformation. AP-1 proteins can function as anti-
oncogenic factors, by inducing apoptosis, or as oncogenic factors, by signalling cell  survival 
(Eferl & Wagner, 2003; Hess et al, 2004; Shaulian & Karin, 2002; Verde et al, 2007). Multiple 
different stimuli induce AP-1, including cytokine, growth factors, neurotransmitters, 
hormones, bacterial and viral infections, stress signals, and oncogenic stimuli. Its activity 
can be regulated at the levels of transcription of the genes encoding AP-1 subunits, mRNA 
stability and translation, protein turnover, and posttranslational modification (Vesely et al, 
2009). AP-1 transcriptional activity is controlled by ROS and reactive nitrogen species (RNS) 
at several levels of its regulation. This includes the regulation of expression of the genes 
encoding AP-1 subunits, the interactions of the AP-1 proteins with their DNA-binding sites, 
their interactions with co-activators, as well as at the level of chromatin remodelling, 
through the modulation of histone acetyltransferase and histone deacetylase (Shlomai, 
2010). 
Abnormal redox regulation of AP-1 has been reported in melanoma (Yang & Meyskens, 
2005). Treatment of human metastatic melanoma cells with resveratrol, a potent ROS 
scavenger, produces some morphological changes, such as reduced anchorage-independent 
growth and decreased AP-1 binding and transcriptional activities. These changes in AP-1 
activities were related to different AP-1 composition, where c-Jun/JunD/Fra1 turned to 
JunD/Fra1/Fra2, with increased levels of JunD, Fra1, and Fra2 expression in the nucleus. 
Furthermore, the overexpression of Fra2 in human melanoma cells reduced significantly 
both AP-1 transcriptional activity and 12-O-tetradecanoylphorbol-induced transcriptional 
transactivation. Addition of H2O2 partially reversed the inhibition of colony proliferation. 
Although H2O2 restored participation of c-Jun in AP-1 complexes, H2O2 addition did not 
affect the induction of Fra1 and Fra2 by resveratrol nor the morphological changes. The 
authors hypothesized that alterations in AP-1 composition and reduction of intracellular 
oxidative status by resveratrol might contribute to the recruitment of normal AP-1 
transcription signalling in melanoma and subsequently induce cellular biological features 
consistent with a more normal phenotype. 
2.3.1.4 Forkhead box O (FoxO) family of transcription factors  
FoxO transcription factors regulate development, proliferation, survival and longevity. 
Members of the mammalian FoxO family, which include FoxO1, FoxO3, FoxO4 and FoxO6, 
are relatively expressed in an ubiquitous way. However, FoxO proteins are not equally 
expressed in all tissues, thus individual FoxO proteins may have specificity in regards to 
cellular function (Maiese et al, 2009). Moreover, target gene regulation appears to be 
controlled in a cell-type-specific manner due to association of FoxO isoforms with specific 
cofactors. Many of the cellular processes modulated by FoxO are themselves deregulated in 
tumorigenesis, and deletion of FOXO genes has demonstrated that these transcription 
factors function as tumour suppressors (van der Vos & Coffer, 2011). FOXOs were originally 
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identified as downstream components of insulin/insulin-like growth factor signalling 
through phosphoinositide 3-kinase (PI3K) and AKT (Brunet et al, 1999; Kops et al, 1999). In 
mice, FoxOs act as functionally redundant tumour suppressors (Paik et al, 2009), and in cell 
systems, FoxOs can either mediate apoptosis or quiescence in response to growth factor 
deprivation (Medema et al, 2000). The DNA binding domain (DBD) is highly conserved 
between FoxO proteins. FoxOs can function both as transcriptional activators and 
repressors, depending on the associated cofactors that they recruit upon DNA binding. 
Growth factors, cytokines, and hormones negatively regulate FoxO transcriptional activity 
through inhibitory phosphorylation predominantly mediated by AKT. 
Regulation of FoxOs by ROS occurs through numerous posttranslational modifications (van 
der Horst & Burgering, 2007). Besides, FoxO activation increases resistance to oxidative 
stress through transcription of antioxidant enzymes as MnSOD and catalase as a result of a 
negative feedback loop (Kops et al, 2002). 
It has been described that FoxO4 is involved in oncogene-induced senescence (OIS) through 
redox mechanisms. Oncogenic BRAF signalling through mitogen-activated protein 
kinase/extracellular signal-regulated kinase kinase results in increased ROS levels and JNK-
mediated activation of FoxO4 via its phosphorylation, which induces p21CIP1-mediated cell 
senescence (de Keizer et al, 2010). In this sense, the ectopic introduction of FoxO4 in 
endogenous oncogenic BRAF-expressing melanoma cells induces a growth arrest through 
cellular senescence (de Keizer et al, 2010). OIS represents a barrier for tumour formation, 
and consequently, the melanoma cells have to bypass this barrier, suggesting that FoxO 
inactivation is one of the requirements for senescence bypass and melanoma growth (de 
Keizer et al, 2010). 
2.3.1.5 p53 tumour suppressor protein  
The tumour suppresor protein p53 (encoded by TP53 gene) is an important transcription 
factor that is induced in response to many forms of cellular stress. This protein has been 
named ‘‘the guardian of the genome’’ because it plays a central role in coordinating the 
cellular responses to a broad range and levels of cellular stress factors, leading to apoptosis, 
cell cycle arrest, senescence, DNA repair, changes in cell metabolism, or autophagy (Green 
& Kroemer, 2009; Helton & Chen, 2007). There are hundreds of p53 DNA-specific binding 
sequences located close to promoters of target genes in the human genome. 
The role of redox signalling in the regulation of p53 has been well demonstrated. The p53 
DNA-binding activity depends on redox regulation by the oxidation of several reactive 
cysteine residues located within its DNA binding domain (Hainaut & Mann, 2001). ROS can 
also regulate the function of p53 through indirect oxidative modifications of its interacting 
partners such as Mdm2 (Shlomai, 2010). Moreover, it was demonstrated that p53 regulates 
energy metabolism and its resulting ROS generation by modulating the transcription of p53 
target genes that control mitochondrial respiration, glycolysis, and the pentose phosphate 
shunt (Bensaad & Vousden, 2007).  
Approximately half of human cancers were found to have inactivating mutations of TP53.  
Although most melanomas have wild type TP53, loss of function of p53 is rather common. 
This protein is kept inactive and at low levels predominantly bound to Mdm2, targeting it 
for proteasomal degradation (Box & Terzian, 2008).  
2.3.1.6 Microphthalmia-associated transcription factor (MiTF)  
MITF is the master control gene for melanocyte lineage survival. The mutation of MITF gene 
causes a microphthalmia phenotype in mice, deafness and lack of pigmentation 
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(Steingrimsson et al, 2004). In humans, mutations of MITF gene cause Waardenburg 
syndrome type IIA in which patients exhibit deafness and pigment disturbances because of 
a lack of melanocytes (Tassabehji et al, 1994). The role of MiTF in differentiation and 
development is well established, but evidence of its role in tumorigenesis remains 
contradictory. In human melanocytes transfected with mutant BRAF, overexpression of 
MiTF leads to transformation (Garraway et al, 2005). As the MITF gene is amplified in some 
melanomas, it has been suggested that MITF can function as a melanoma oncogene (Levy et 
al, 2006). In another report, however, MiTF was downregulated in Braf-transformed murine 
melanocytes and BRAF-expressing human melanocytes; reexpression of MiTF in these cells 
inhibited cell proliferation (Wellbrock & Marais, 2005). These contradictions have been 
elegantly reconciled in a recent review that has pointed out that an optimal amount of MiTF 
is required for maintaining proliferation and differentiation, whereas MiTF levels that are 
too low or too high may cause cell-cycle arrest and apoptosis (Gray-Schopfer et al, 2007). 
It has been demonstrated that MiTF regulates cellular response to ROS by upregulating 
APE-1 at the basal level as well as enhancing its stimulation by ROS (Liu et al, 2009). APE-1 
has two essential well characterized functions: a DNA endonuclease activity, which has a 
key role in the base excision DNA repair pathway and a role as redox sensor that enhances 
the DNA binding activities of a large number of transcription factors, including p53, HIF-1ǂ, 
AP-1, and NF-κB upon an increase of intracellular ROS. Depletion of APE-1 by siRNA leads 
to apoptosis in human cells due to accumulation of damaged DNA, especially when ROS 
increase (Fung & Demple, 2005).  
2.3.2 Redox regulation in the melanoma signalling network 
Melanocyte and melanoblast proliferation, survival, differentiation and migration are all 
critical elements of normal developmental physiology. The signalling circuitry that regulates 
these events is often indelibly altered at the genetic level by the potential melanoma cell 
(Fig. 4). 
At least four major signalling abnormalities have been described in melanoma. They include 
the Ras signalling network, both through RAF/ERK MAPK and PI3K/AKT cascades; the 
p16INK4A/CDK4 network; the Bcl-2/p53 network and the melanocyte developmental 
pathways that involve receptor tyrosine kinase (KIT), microphtalmia transcription factor 
(MITF) and ǃ-Catenin. The abnormalities in these signalling cascades are involved in the 
different steps of promotion and progression of melanoma, from the radial growth, the 
resistance to apoptosis and radio- and chemotherapy up to the vertical growth and the 
invasion and metastasis processes (Hocker et al, 2008).  
2.3.2.1 The Ras signalling network 
The Ras signalling network regulates cell growth, cell proliferation, survival and invasion 
through two distinct cascades, the Ras/MAPK and the Ras/PI3K signalling streams. 
One of the first genes shown to be specifically mutated in melanoma was NRAS, a gene 
encoding a member of the Ras family of small GTP-binding proteins (Berger & Garraway, 
2009). These proteins lie at the top of the Ras/Raf/MEK/ERK MAPK pathway. This 
activates a large number of growth-promoting genes in response to growth factors and 
cytokines. NRAS is mutated in 15-30% of melanomas (Demunter et al, 2001; van Elsas et al, 
1996). These mutations impair GTPase catalytic activity of Ras, resulting in a constitutively 
GTP-bound and active state. It has been suggested that the spatial distribution of NRAS-
mutated tumours on the skin and their proclivity for dipyrimidine mutations have a 
possible correlation with UV exposure (Berger & Garraway, 2009). 
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As noted above, Ras works in the MAPK pathway (Fig. 2A and 4). This pathway is 
hyperactivated in up to 90% of human melanomas (Cohen et al, 2002). This emphasizes the 
contribution of NRAS mutations to the development of melanoma but also indicates the 
involvement of other genes in the pathway. The BRAF gene was observed to be mutated in 
80% of short-term melanoma cell cultures and 66% of uncultured melanomas thereby 
making BRAF the single most commonly mutated gene in melanoma (Hocker et al, 2008). 
The product of BRAF gene is a serine-threonine kinase that induces MEK to phosphorylate 
ERK, which enhances cell growth and proliferation (Berger & Garraway, 2009). Notably, up 
to 90% of the BRAF mutations in melanoma involved a single substitution of valine to 
glutamic acid in the kinase domain (V600E) (Berger & Garraway, 2009; Davies et al, 2002). 
The oncogenic potential lies in the ability of the V600E mutant to lead to a constitutively 
active BRAF product (Berger & Garraway, 2009; Davies et al, 2002; Shinozaki et al, 2004; 
Wan et al, 2004). Unlike the mutation patterns observed in NRAS, the T>A transversion at 
the 1799 position associated with the V600E mutation is not suggestive of UV-induced DNA 
damage, although there is an apparent association between this mutation and intermittent 
exposure to sun (Maldonado et al, 2003). Thus, mutations in both NRAS and BRAF occur in 
a mutually exclusive manner suggesting some degree of functional redundancy between 
these genetic events (Hocker et al, 2008). 
Once activated, Ras induces the membrane translocation and activation of PI3K, which leads 
to activation of a prominent downstream oncogenic effector, AKT (Fig. 2A and 4). 
Downstream effectors of AKT promote proliferation, survival and invasion (Hocker et al, 
2008). Downstream components of the PI3K pathway have been shown to be altered in up to 
50-60% of melanomas (Stahl et al, 2004; Zhou et al, 2000) The expression of PI3K and AKT 
have shown to gradually increase during the progression from benign nevi to early 
melanoma, and finally, to metastasic disease (Hocker et al, 2008; Stahl et al, 2004). 
Interestingly, the AKT3 isoform is highly expressed in neural crest-derived cells such as 
melanocytes, and AKT3 has been found undergo chromosomal copy gains and/or 
overexpression in up to 60% of melanomas (Stahl et al, 2004). Moreover, activating point 
mutations in AKT3 have also been described in melanoma (Davies et al, 2008). 
A key downstream component of the PI3K pathway, PTEN (also named PTEN/MMAC1), is 
frequently altered in melanoma and is thought to be one of the main mediators of PI3K 
pathway activation and melanoma tumorigenesis (Fig. 4). Deletions or loss-of-function 
mutations in PTEN were observed in 40% of melanoma cell lines (Guldberg et al, 1997; Wu 
et al, 2003). Inactivating mutations in PTEN and activating mutations in NRAS were proved 
to exist in reciprocal fashion. This suggests that the loss of PTEN and the activation of NRAS 
product may functionally overlap (Hocker et al, 2008). The protein PTEN is involved in the 
termination of PI3K signalling, upregulation of cell cycle arrest and proapoptotic proteins, 
and downregulation of antiapoptotic proteins of the Bcl-2 family. The expression of PTEN is 
lost or decreased in 15-50% of melanomas even in the absence of demonstrable mutations 
(Zhou et al, 2000). Remarkably, ROS participate as second messengers both in RAF/MAPK 
and PI3K/AKT cascades stimulating cell proliferation (Fig. 2A and 4). ROS often go along 
with aberrant Ras signalling, either caused by oncogenic forms of the protein or by strong 
upstream growth factor signalling through the Ras/Raf/MAPK pathway (Finkel, 2006; 
Kopnin et al, 2007). Moreover, Ras can be activated by UV radiation, ROS, metals and 
mitogenic stimuli (Valko et al, 2006). It has been reported that the serine/threonine kinases 
of the MAPK family can be regulated by oxidants. In this sense, O2●–  and H2O2 can activate 
the MAPK cascade at the level of MEK and ERK1/2 (Valko et al, 2006). Disregulation of 
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MAPK function was found in human skin cancers (Valko et al, 2006) and this pathway is 
invariably activated in early-, intermediate-, and last-stage melanomas (Verhaegen et al, 
2006). Moreover interplay among the MAPK pathway, ROS and antiapoptotic factors in the 
control of melanoma viability was demonstrated. Verhaegen et al reported a tumour cell-
selective role of the MAPK pathway upstream of the mitochondria, controlling ROS 
production. This function was critical to prevent the activation of proapoptotic functions of 
p53 in melanoma cells, but it was dispensable for normal melanocytes (Verhaegen et al, 2006). 
In addition to PTEN and BRAF mutations, proto-oncogene pathway activation can occur in 
melanoma as a result of ROS potentiating AKT signalling by inhibition of PTEN 
phosphatase activity (Fruehauf & Trapp, 2008). Moreover, as described in 2.3.1.2 section, the 
NF-κB transcription factor is constitutively active in melanoma (Meyskens et al, 1999). 
Furthermore, it is well known that this transcription factor is usually activated under 
prooxidant conditions (Stone & Yang, 2006). Govindarajan et al. found that O2●– can be 
induced by AKT in melanoma, and AKT can prevent cells from superoxide mediated cell 
death. Thus AKT may serve as a molecular switch that enhances aggressiveness through 
tumour angiogenesis and the generation of O2●–. The payoff for the tumour is generating 
ROS-NF-κB signalling, which allows increased angiogenesis and resistance to chemotherapy 
(Govindarajan et al, 2007).  
2.3.2.2 The p16INK4A/CDK4/Cyclin D1 network 
Although NRAS and BRAF play a key role in melanocytes proliferation, activating 
mutations in those genes are alone insufficient to lead to malignant transformation. 
Consequently the requirement for cooperation of other pathways is highlighted. In order for 
malignant transformation to occur, the mechanisms that mediate senescence must be 
overridden. Oncogene-induced senescence is thought to involve activation of tumour 
suppressors such as CDKN2A, RB and TP53 (Mooi & Peeper, 2006). Increased susceptibility 
to melanoma was observed in patients with germline mutations in these genes. The 
CDKN2A gene encodes two proteins: p16INK4A and p14ARF, and both of them are involved in 
melanoma growth and survival (Sharpless et al, 2003). The p16INK4A protein inhibits the 
phosphorylation of the retinoblastoma protein by CDK4/6. On the other hand, p14ARF 
inhibits the p53 antagonist Mdm2 and it is suggested that p14ARF also possessed tumour-
suppressive effects that are independent of p53 (Ha et al, 2007). Thus CDKN2A appears to 
play a major role in preventing cancer formation by mediating a senescence-like state upon 
oncogenic stress (Hocker et al, 2008; Serrano et al, 1997) Melanoma cell lines often exhibited 
loss of both CDKN2A copies (Fig. 4). Those that retain at least one copy of CDKN2A 
frequently carried nonsense, missense or frameshift mutations of the remaining allele 
(Hocker et al, 2008). This loss of CDKN2A is required in addition to NRAS mutations in 
order to progress to frank melanoma (Hocker et al, 2008).  
Moreover, both somatic and germline mutations in CDK4 have been detected in melanoma 
(Hocker et al, 2008). The mutations in CDK4 fall in the p16INK4A binding region (Lys22 or 
Arg24) and prevent p16INK4A from binding to and inhibiting CDK4 protein (Hocker et al, 
2008). Thus, these alterations in CDK4 mimic p16INK4A loss. 
Cyclin D (encoded by CCND1) is another fundamental component of the CDK4/6 complex. 
Oncogenic Ras positively impacts the cell cycle by upregulating cyclin D1 through MAPK 
signalling, drawing another link between Ras network and p16INK4A/CDK4 network (Fig. 4). 
A less common melanoma subtype, acral lentiginous melanoma, frequently exhibits 
amplification of the chromosomal region that encompasses the CCND1 locus (Bastian et al, 
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2000; Sauter et al, 2002). Additionally, CCDN1 amplifications were noted to occur more often 
on melanomas that take place on skin with chronic sun-induced damage (Curtin et al, 2005). 
The tumour-suppressor p16INK4A was recently suggested as an endogenous regulator of 
carcinogenic intracellular oxidative stress and the increased susceptibility of melanocytes to 
elevated ROS in the context of the characteristic oncogenic p16INK4A depletion was reported 
(Jenkins et al, 2010). Considering the importance of cell cycle regulation tightly bound to 
Ras/MAPK and PI3K/AKT signalling cascades and to the p16INK4A/CDK4 network, we 
studied the effects of ROS modulation on cell cycle and we demonstrated that the high 
levels of intracellular ROS of melanoma cells are associated with increased levels of cyclin 
D1 and mislocalization of the negative regulatory protein of Cyclin/CDKs complexes, 
p27KIP1 (unpublished results), favouring the increased proliferation rate of melanoma cells 
(Fig. 2A). Notably, cyclin D1 expression is directly controlled by Ras/MAPK pathway and 
ROS (Burhans & Heintz, 2009). 
2.3.2.3 The Bcl-2/p53 apoptotic pathways  
It has been shown that alterations within apoptotic pathways, as well as aberrant 
modulation by upstream signalling networks, such as MAPK and PI3K, contribute to the 
inherent chemoresistance observed in melanoma (Helmbach et al, 2001; Hocker et al, 2008). 
The protein p53 functions to initiate DNA repair and/or apoptosis when exposed to cellular 
stresses, such as UV radiation or high levels of ROS (Fig. 2B). The overall mutational rate in 
melanoma of this gene is near to 13% (Hocker & Tsao, 2007). As described in Section 2.3.1.5, 
direct mutation of TP53 is rare in sporadic melanoma, whereas p53 is frequently inactivated 
(Sekulic et al, 2008). Induction and activation of p53 play an essential role in halting cellular 
growth and repairing damaged DNA under conditions of substantial cellular stress. An 
important mediator of the cell cycle-inhibitory function of p53 is the cell cycle inhibitor 
p21CIP1, which is induced by p53 and inhibits the cyclin E-CDK2 complex. This leads to 
decreased phosphorylation of Rb protein with the consequent cell cycle arrest at the G1/S 
transition point. Thus, melanoma cells can increase their proliferation rate taking advantage 
of their high levels of ROS and the defective function of p53 (Fig. 4). 
The Bcl-2 network is one of the most crucial regulators of melanoma cell apoptosis (Soengas 
& Lowe, 2003). The Bcl-2 family is formed by both antiapoptotic and proapoptotic members. 
Bcl-2 protein has a physiologic role in the skin: in response to UV radiation, keratinocytes 
secrete NGF, which binds to melanocyte receptors and leads to increased Bcl-2 expression 
and resistance to apoptosis (Zhai et al, 1996). Aberrations in various signaling pathways 
contribute to elevated Bcl-2 levels in melanoma. Particularly, oncogenic NRAS and MITF 
favour the enhanced expression of this antiapoptotic protein in melanoma (Hocker et al, 
2008). Alterations in others antiapoptotic members of the Bcl-2 family, such as Mcl-1, may 
play a role in decreasing the dependence on Bcl-2 for cell survival. Indeed, Mcl-1 has 
emerged as potentially critical melanoma survival gene and is highly expressed in primary 
as well as advanced melanoma (Tang et al, 1998). Various growth factor receptors on the 
melanoma cell surface signal through AKT to increase the levels of the Bcl-2 family proteins 
that can block apoptosis and this could be mediated by ROS (Fruehauf & Trapp, 2008) 
2.3.2.4 Melanocyte developmental pathways alterations 
The genetic factors involved in the coordinated balance of proliferation, migration and 
survival required for melanocyte homing to the cutaneous surface may be usurped by 
melanoma cells during tumorigenesis. 
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KIT is an essential gene for melanocyte survival and development, which encodes a receptor 
tyrosine kinase (RTK) for the stem cell factor (SCF) ligand and functions as an upstream 
activator of the MAPK signalling pathway (Berger & Garraway, 2009). The role of KIT in 
melanoma tumorigenesis is rather controversial (Hocker et al, 2008). The fact that KIT 
alterations are associated with certain less common types of melanoma, would explain the 
relatively low frequency of mutations of this gene in unselected cases (Hocker et al, 2008). 
However, in uveal melanoma, c-Kit expression is present in nearly 80% of cases (Berger & 
Garraway, 2009; Sekulic et al, 2008). It is generally accepted that ROS generated by these 
ligand/receptor-initiated pathways can function as true second messengers and mediate 
important cellular functions such as proliferation and programmed cell death (Valko et al, 
2006). Indeed, ROS act as second messengers in the MAPK pathway activated by KIT and 
they can mediate uveal melanoma cell proliferation through this signalling. 
The MITF gene has emerged as a master regulator of melanocyte development (Hocker et al, 
2008). As described in section 2.3.1.6, its product is a transcription factor involved in 
multiple processes, such as the regulation of pigment cell phenotype and melanocyte 
proliferation and survival (Widlund & Fisher, 2003). Interestingly, MITF amplifications are 
coincident with mutations in BRAF (Berger & Garraway, 2009). Unlike oncogenic NRAS and 
BRAF, which acquire new and tumour-specific cellular functions through nucleotide 
mutations, MITF becomes oncogenic via deregulation, affecting survival mechanisms that 
are also present in the normal melanocyte lineage (Berger & Garraway, 2009).  
MiTF is a downstream target of ǃ-catenin, a critical regulator of melanoma cell growth 
(Widlund et al, 2002) which, in turn,  is an important downstream mediator of Wnt pathway 
signalling (Hocker et al, 2008). Thus, melanomas often show constitutive activation of the 
Wnt signalling as revealed by nuclear accumulation of ǃ-catenin (Rimm et al, 1999). Wnts 
are secreted proteins with important developmental functions, particularly in neural crest 
cells such as melanocytes (Sekulic et al, 2008). The Wnt signalling pathway is also regulated 
by ROS (Fig. 4). A thioredoxin-related protein, nucleoredoxin (NRX), governs ROS-
stimulated Wnt signalling in a temporal manner (Funato & Miki, 2010). NRX usually 
interacts with Dishevelled (Dvl), an essential adaptor protein for Wnt signalling, and blocks 
the activation of the Wnt pathway (Funato & Miki, 2010). Oxidative stress causes 
dissociation of NRX from Dvl, which enables Dvl to activate the downstream Wnt signalling 
pathway (Funato & Miki, 2010). 
Gene transcription and post-translational modifications of MiTF are strongly influenced by 
multiple upstream pathways, some of which are modulated by ROS, such as RTK, MAPK 
and PI3K pathways (Fig. 4). Therefore, some authors linked the involvement of ROS in these 
signalling pathways to the progression of melanoma by the term reactive oxygen-driven 
tumour (Fried & Arbiser, 2008). In this sense, the overexpression of APE-1, a transcriptional 
target for MiTF, protected melanoma cells from H2O2-induced cell death (Yang et al, 2005). 
Interestingly, Liu et al. demonstrated that MiTF regulates cellular ROS response by 
upregulating APE-1. Thus, MiTF-positive melanoma cells are more resistant to H2O2-
induced cell death as compared to MiTF-negative cells. MiTF accumulation in advanced 
melanoma may increase APE-1 levels and other survival factors such as Bcl-2, which in turn 
lead to better survival outcome for tumour cells (Liu et al, 2009). This is associated to the fact 
that high MiTF levels were correlated with poor outcome of patients with melanoma 
(Koyanagi et al, 2006). 
As we can see so far, the melanoma network is highly interconnected with a great deal of 
functional redundancy built into it. The signalling pathways active in melanoma cells are 
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interconnected through multiple feedback loops, and ROS are involved in the regulation of 
many of them (Fig. 4). 
 
 
Fig. 4. ROS and the altered signalling pathways involved in the different steps of promotion 
and progression of melanoma. 
2.4 ROS in invasion and metastasis of melanoma 
Regarding the involvement of ROS in metastatic melanomas, several proteins related to 
different steps of migration, invasion and metastasis have been found to be induced by 
transcription factors or activated by signalling pathways described as mediated by ROS. For 
example, connexin 43 (Cx-43), which participates in tumour cell diapedesis and attachment 
to endothelial cells (Villares et al, 2009) along with a chondroitin sulfate proteoglycan of the 
extracellular matrix that favours the detachment of cells and the metastatic dissemination 
(Domenzain-Reyna et al, 2009), i.e. versican, are overexpressed in melanomas and are 
regulated by the redox-responsive transcription factor AP-1. Another mechanism that 
relates high ROS levels of melanoma cells to metastatic potential would be the cytoplasmic 
mislocalization of p27KIP1 (unpublished results), since reduced nuclear levels of this protein 
increases proliferation and cytoplasmic localization would drive tumour cell invasion by 
other functions of this protein not related to cell cycle regulation (Wander et al, 2010). 
NEDD9 has been supported as a melanoma gene important for invasion and metastasis 
(Kim et al, 2006). The overexpression of this gene induces malignant features related to 
metastatic potential in primary melanocytes and in nonmetastatic melanoma cells. This 
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increased invasiveness is conferred by a functional and physical interaction between 
NEDD9 and focal adhesion kinase (FAK) at the cell periphery (Berger & Garraway, 2009).  
Hef1 (encoded by NEDD9) positively regulates the Src-FAK-Crk “migratory switch”. Hef1 
overexpression also induces the activation of ERK, p38, and JNK kinases through 
interactions with intermediary signalling effectors. As previously explained, these proteins 
that interact with Hef1 can be modulated by ROS (O'Neill et al, 2007). 
Angiogenesis signalling in melanoma is mediated by growth factor receptors, including the 
VEGF, platelet-derived growth factor (PDGF), and basic-fibroblast growth factor (b-FGF) 
pathways. VEGF activation of VEGF receptors (VEGFR) is likely to play an important role in 
melanoma growth, survival, and invasiveness through autocrine loop formation (Graells et 
al, 2004; Lacal et al, 2005). As described above, ROS can modulate these pathways involved 
in angiogenesis (Fig. 4). In this sense, it has been well described that the expression of VEGF 
is induced by ROS and in particular it is most strongly activated by H2O2 (Valko et al, 2006). 
3. Therapeutics approaches for melanoma based on reactive oxygen species 
levels 
It is widely accepted that melanoma is resistant to all therapeutic modalities once the 
metastatic process started. Current treatment protocol for early-stage melanomas consists in 
surgical tumour excision, while in advanced stages, the adjuvant treatment including 
chemotherapy, unspecific immunotherapy and interferon offers poor results regarding free 
disease terms rate of survival. Thus, none of the currently available FDA approved therapies 
clearly alter the natural history of the disease for the population as a whole. 
On the other hand, advanced personalized therapeutic procedures like golden nanospheres 
and gene therapy are recently being studied and represent an alternative for future 
treatment of melanoma. Despite all new knowledge and technological support the advanced 
stage melanoma management still remains an unsolved problem. 
3.1 Use of ROS as therapeutic agents  
The cytotoxic nature of ROS has been widely used to kill tumour cells in many cancer 
treatments. Various anti-cancer agents in clinical use today―including anthracyclines, 
cisplatin, bleomycin and ionizing radiation―generate ROS within the cells (Nishikawa, 
2008). However, around a decade ago, the concept of taking advantage of the increased 
oxidative stress of cancer cells was proposed as a strategy to induce preferential cancer cell 
death based on the different redox states in normal and malignant cells. Different 
approaches exploit the fact that increased ROS may induce cell death by apoptosis.  
Arsenic trioxide (ATO) is studied as an anticancer agent whose use originated in traditional 
Chinese medicine. In several tumour types, it is an established cell growth inhibitor and 
apoptosis inducer (Baysan et al, 2007; Han et al, 2008). In patients with acute promyelocytic 
leukemia, for example, low concentrations of ATO (less than or equal to micromolar 
concentrations) induce longlasting remission without significant myelosuppressive side 
effects. The ability of ATO to induce apoptosis in leukemic cells depends on the activity of 
the enzymes that regulate cellular H2O2 content (Jing et al, 1999). Regarding melanoma and 
ATO, in several melanoma cell lines a study demonstrates that a combination of treatments 
of melanoma cells with ATO and the antibiotic thiostrepton results in significant growth 
inhibitory effects, reversed when the cells are also treated with the free radical scavenger 
NAC, indicating an increase in intracellular ROS as part of the mechanism. Thiostrepton is 
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commercially available as part of a topical antibiotic mixture used to treat bacterial 
infections in animals. It has also been used to effectively treat murine bacterial systemic 
infections (Bowling et al, 2008). However, to date, it has not been approved for human use. 
Other drugs are studied alone or in combination with ATO to induce apoptosis. Disulfiram 
(DSF), an agent used to treat alcoholism for the past few decades, has been shown to induce 
apoptosis in thymocytes. It has been demonstrated that redox regulations in melanoma cells 
are aberrant and metal chelators (such as dithiocarbamate) alter the redox status and induce 
apoptosis in melanoma cells. Cen et al. have explored the effect of disulfiram (DSF), a 
member of the dithiocarbamate family, on apoptosis in melanoma cells, founding that DSF 
caused a 3 to 5-fold increase in apoptosis in all three melanoma cell strains being tested at a 
very low dose (25-50 ng/ml). The same dose of DSF did not have significant apoptotic effect 
on melanocytes (Cen et al, 2002). Disulfiram in combination with ATO were selected for a 
study based on their ability to alter GSH redox balance. They were chosen because ATO has 
been reported to be synergistic against various solid tumour cell lines in vitro and in vivo 
when given with buthionine sulfoximine (BSO), another agent that acts as DSF, both 
modulating GSH metabolism (Wu et al, 2004); and the effect of Disulfiram (DSF), has 
recently been explored on apoptosis in melanoma cells. 
Another compound that showed therapeutic activity in malignant melanoma is Elesclomol 
(STA_4783), that was able to prolong the progression-free survival time in a Phase II clinical 
trial (Kirshner et al, 2008). The mechanism underlying proapoptotic activity of elesclomol is 
through the induction of ROS and oxidative stress. Elesclomol rapidly induced ROS in 
cancer cells, generating a transcription profile characteristic of an oxidative stress response. 
Moreover, pretreatment of cells with antioxidants blocked all in vitro activities associated 
with elesclomol, including ROS production and the induction of apoptosis.  Unfortunately, 
the Phase III clinical trials of elesclomol were suspended in 2008 due to safety concerns. 
Finally, Taxol (paclitaxel) is a chemotherapeutic agent that has shown promise in the 
treatment of previously unresponsive breast, ovary, and non-small cell lung carcinoma 
(Crown & O'Leary, 2000). It interferes with mitosis during the G2/M phase of the cell cycle. 
Besides, it was demonstrated that taxol mediated activation of MAPK signalling pathways is 
linked to the activation of the cell death machinery in human melanoma cell lines. The same 
study demonstrates that the downregulation of a protein UCP2 and subsequent induction of 
ROS are essential parts in this mechanism (Selimovic et al, 2008). 
ROS are capable of exerting different effects according to their nature, localization and levels 
(Davies, 2000). Although classically they are thought of as cytotoxic and mutagenic or as 
inducers of oxidative stress, evidence show that ROS play a role in signal transduction. ROS 
can be implicated in stimulation or inhibition of cell proliferation, apoptosis, and cell 
senescence (Chen, 2000; Sundaresan et al, 1995). In BHK-21 and human prostate cells, a low 
concentration of exogenously added H2O2 caused a modest increase in proliferation, 
whereas higher levels resulted in slowed growth, cell cycle arrest, and/or apoptosis 
(Burdon, 1996; Wartenberg et al, 1999).  
Furthermore, considering the relationship between ROS and metastasis, reviewed in the 
literatures, it indicates that ROS accelerate adhesion (Orr et al, 2000), invasion (Orr et al, 
2000), migration (Wu, 2006; Wu et al, 2008) and angiogenesis (Ushio-Fukai & Nakamura, 
2008). Therefore, ROS scavengers, such as catalase and superoxide dismutase, have been 
examined to inhibit tumour metastasis, although their effects are not very marked. Targeted 
delivery of these enzymes to the sites where ROS are generated is necessary to obtain 
sufficient inhibition of tumour metastasis. 
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Thus, an increase in ROS levels is not the only alternative for a possible cancer therapy. 
Scavenging of H2O2 in several tumour cells inhibits cell proliferation (Arnold et al, 2001). 
The inhibition of lung metastatic tumour growth of melanoma cells has been reported to 
occur in a mouse model by sustained delivery of catalase (Hyoudou et al, 2009). In that 
sense, a recent study of our group demonstrates that H2O2 scavenging impedes nuclear 
exportation of p27KIP1 allowing cell cycle arrest through the accumulation of this protein in 
the nucleus (unpublished data).  
Interleukin (IL)-2 has been shown to have clinical activity in metastatic melanoma. 
Nevertheless, in vitro studies have demonstrated that ROS generated by 
monocyte/macrophage populations may inhibit cytotoxic activity within the tumour, 
leading to the hypothesis that cytokine-based immunotherapy may be more effective if the 
generation of ROS were inhibited (Hansson et al, 1999; Kono et al, 1996). Clinical evidence in 
support of this hypothesis came from phase II studies that combine histamine, a potent 
inhibitor of ROS formation, with cytokine-based therapies for metastatic melanoma, acute 
myelogenous leukemia, and renal cell carcinoma (Hellstrand et al, 1997; Hellstrand et al, 
1994). 
Manipulating ROS levels by redox modulation is a way to selectively kill cancer cells 
without causing significant toxicity to normal cells. It is worth noting that redox alterations 
in cancer cells are very complex because of the multiple factors involved in the redox 
regulation and stress response, and that the simple addition of ROS-generating agents may 
not always lead to a preferential killing of cancer cells. This explains the importance of 
understanding the complex redox alterations in cancer cells. 
3.2 Gene therapy 
Gene Therapy is a relatively new paradigm for treatment of human diseases and is 
becoming a rationale area for the development of new therapeutic agents for cancer 
treatment. One major strategy of gene therapy to provide effective and specific activation of 
medical products inside the tumour mass implicates the control of the therapeutic agent 
activity by a Tumour Specific Promoter (TSP). TSPs corresponding to genes differentially 
activated in cancer cells have been used to control viral replication inside the tumour or the 
antitumour activity of therapeutic genes in melanoma (Cao et al, 1999; Diaz et al, 1998; 
Schoensiegel et al, 2004). Selection of a TSP is central for the design of a well defined medical 
product for gene transfer. Since solid tumours are highly heterogeneous it is more tempting 
to drive gene expression by designing promoters that include transcriptional regulatory 
elements responsive to the tumour environment conditions (Laurent et al, 2005). 
Recently, we described a novel approach of gene therapy, which takes advantage of the 
prooxidant state of melanoma cells. (Policastro et al, 2009).  This therapeutic strategy is 
based on a ROS-responsive chimeric promoter, containing a ROS-response motif located in 
the VEGF gene promoter and a second ROS-response motif obtained from the EGR1 gene 
promoter. This chimeric promoter was based on a ROS-response motif located in the VEGF 
gene promoter placed and a second ROS-response motif obtained from the EGR1 gene 
promoter. The activity of the chimeric promoter (named E6(40)VE) was largely dependent 
on variations in intracellular ROS levels and showed a high inducible response to exogenous 
H2O2. Transient expression of the Herpes Simplex virus thymidine kinase therapeutic gene 
(TK) driven by the chimeric promoter, followed by gancyclovir administration, inhibited 
human melanoma cells growth in vitro and in vivo. Moreover, electrotransfer of the TK gene 
followed by GCV administration exerted a potent therapeutic effect on melanoma 
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established tumours. This response was improved when combined with chemotherapeutic 
drugs such as doxorubicin, which act by themselves by increasing ROS levels (Policastro et 
al, 2009). 
4. Conclusion 
Throughout this review, we summarized the updated knowledge about the involvement of 
ROS in the biology of melanoma, analyzing the alterations in both, specific pathways of 
melanocytes development and general ROS-regulated signalling pathways common to 
different types of tumours. Moreover, we provided a glimpse of the state-of-the-art 
advances in relation to therapeutic approaches for melanoma treatment in view of the high 
levels of ROS characteristic of melanoma cells as a differential feature that may be exploited 
to develop selective treatments with low toxicity for normal tissues. 
Further studies on the biology of melanoma and ROS regulation in the context of recent new 
advances in genomics, proteomics and bioinformatics will allow a better comprehension of 
the complex signalling network in response to the high oxidative stress of melanoma. This 
approach will help to characterize individual patient tumour specimens identifying 
vulnerable targets and preventing deleterious damage in normal tissues.  
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